An open six-week study of the efficacy of agomelatine was performed in 35 patients with single depressive episodes or recurrent depression (ICD-10 diagnoses) and clinically severe anxiety. Agomelatine was found to be highly effective and safe in the treatment of mild and moderate depression combined with anxiety disorders. Decreases in the severity of the symptoms of depression and sleep disorders were seen from treatment week 1, with reductions in anxiety from treatment week 2. By the end of the study, therapeutic effects were seen in 71.9% of patients and the remission criteria were achieved in 68.8% of patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
O. P. Vertogradova, “Possible approaches to the typology of depression,” in: Depression (psychopathology, pathogenesis), Moscow (1980), pp. 9–15.
V. N. Krasnov, Affective Spectrum Disorders, Moscow (2011), pp. 146–156.
S. N. Mosolov, E. G. Kostyukova, A. V. Gorodinchev, et al., “Efficacy and tolerance of agomelatine in depressive states,” 15, 15–24 (2011).
A. A. Pribytkov, “Comparative analysis of the antidepressant activity and effects on sleep disorders of agomelatine (Valdoxan) and fluvoxamine (Fevarin),” Obozr. Psikhiatr. Med. Psikhol. im. Bekhtereva, No. 4, 38–40 (2010).
L. B. Allen, K. S. White, and D. H. Barlow, “Cognitive behavior therapy (CBT) for panic disorder: relationship of anxiety and depression comorbidity with treatment outcomes,” J. Psychopathol. Behav. Assess., 32, No. 2, 185–192 (2010).
D. S. Baldwin, C. Allgulander, B. Bandelow, et al., “An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder,” World J. Biol. Psychiatry, 13, No. 7, 510–516 (2012).
B. Bandelow, J. Zohar, E. Hollander, et al., “World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision,” World J. Biol. Psychiatry, 9, No. 4, 248–312 (2008).
D. H. Barlow and L. A. Campbell, “Mixed anxiety-depression and its implications for models of mood and anxiety disorders,” Comp. Psychiatry, 41, No. 2, 55–60 (2000).
J. Das-Munshi, D. Goldberg, P. Bebbington, et al., “Public health significance of mixed anxiety and depression: beyond current classification,” Brit. J. Psychiatry, 192, No. 3, 171–177 (2008).
J. R. Davidson, “First-line pharmacotherapy approaches for generalized anxiety disorder,” J. Clin. Psychiatry, 70, No. 2, 25–31 (2009).
D. R. Dolnak, “Treating patients for comorbid depression, anxiety disorders, and somatic illnesses,” J. Am. Osteopath. Assoc., No. 2, 1–8 (2006).
E. Driessen and S. D. Hollon, “Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators,” Psychiatr. Clin. North Am., 33, No. 3, 537–555 (2010).
P. S. Foroushani, J. Schneider, and N. Assareh, “Meta-review of the effectiveness of computerized CBT in treating depression,” BMC Psychiatry , No. 11, 131 (2011).
G. Gartlehner, R. A. Hansen, and L. C. Morgan, et al., “Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis,” Ann. Intern. Med., 155, No. 11, 772–785 (2011).
A. Hale, R. M. Corral, C. Mencacci, et al., “Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study,” Int. Clin. Psychopharmacol., 25, No. 6, 305–314 (2010).
S. G. Hofman and J. A. Smits, “Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials,” J. Clin. Psychiatry, 69, No. 4, 621–632 (2008).
H. E. Hollander, “Antidepressants in the treatment of depression: the clinician and the controversy,” Am. J. Clin. Hypn., 55, No. 3, 230–235 (2013).
S. Kasper, G. Hajak, K. Wulff, et al., “Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline,” J. Clin. Psychiatry, 71, No. 2, 109–120 (2010).
S. H. Kennedy, S. Rizvi, K. Fulton, et al., “A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR,” J. Clin. Psychopharmacol., 28, No. 3, 329–333 (2008).
S. H. Kennedy and E. Emsley, “Placebo-controlled trial of agomelatine in the treatment of major depressive disorder,” Eur. Neuropsychopharmacol., 16, No. 2, 93–100 (2006).
R. J. Kuzel, “Treating comorbid depression and anxiety,” J. Fam. Pract., 43, 45–53 (1996).
P. Lemoine, C. Guilleminault, and E. Alvarez, “Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine,” J. Clin. Psychiatry, 68, No. 11, 1723–1732 (2007).
M. N. Levitan, M. Papelbaum, and A. E. Nardi, “A review of preliminary observations on agomelatine in the treatment of anxiety disorders,” Exp. Clin. Psychopharmacol., 20, No. 6, 504–509 (2012).
H. Lôo, A. Hale, and H. D’haenen, “Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study,” Int. Clin. Psychopharmacol., 17, No. 5, 239–247 (2002).
A. D. Lopez, C. D. Mathers, M. Ezzati, et al., “Global and regional burden of disease and risk factor, 2001: systematic analysis of population health data,” Lancet, 367, 1747–1757 (2006).
A. McIntyre, A. Gendron, and A. McIntyre, “Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study,” Depress. Anxiety, 24, No. 7, 487–494 (2007).
M. J. Millan, M. Brocco, A. Gobert, et al., “Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade,” Psychopharmacology, 177, No. 4, 448–458 (2005).
N. Mor and D. Haran, “Cognitive-behavioral therapy for depression,” Isr. J. Psychiatry Relat. Sci., 46, No. 4, 269–273 (2009).
J. P. Olié and S. Kasper, “Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder,” Int. J. Neuropsychopharmacol., 10, No. 5, 661–673 (2007).
M. H. Pollack, “Comorbid anxiety and depression,” J. Clin. Psychiatry, 66, No. 8, 22–29 (2005).
A. Qaseem, V. Snow, T. D. Denberg, et al., “Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians,” Ann. Intern. Med., 149, No. 10, 725–733 (2008).
M. A. Quera-Salva, P. Lemoine, and C. Guilleminault, “Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients,” Hum. Psychopharmacol., 25, No. 3, 222–229 (2010).
S. M. Stahl, M. Fava, M. H. Trivedi, et al., “Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial,” J. Clin. Psychiatry, 71, No. 5, 616–626 (2010).
D. J. Stein, A. Ahokas, C. Albarran, et al., “Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study,” J. Clin. Psychiatry, 73, No. 7, 1002–108 (2012).
D. J. Stein, A. A. Ahokas, and C. de Bodinat, “Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study,” J. Clin. Psychopharmacol., 28, No. 5, 561–566 (2008).
F. Wedegaertner, S. Arnhold-Kerri, N. A. Sitgtaro, et al., “Depression- and anxiety-related sick leave and the risk of permanent disability and mortality in the working population in Germany: a cohort study,” BMC Public Health, 13, No. 1, 145 (2013).
S. Wetzler and M. M. Katz, “Problems with the differentiation of anxiety and depression,” J. Psychiat. Res., 23,. No. 1, 1–12 (1989).
A. S. Young, R. Klap, R. Shoai, et al., “Persistent depression and anxiety in the United States: prevalence and quality of care,” Psychiatr. Serv., 59, No. 12, 1391–1398 (2008).
J. Zajecka, A. Schatzberg, S. Stahl, et al., “Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial,” J. Clin. Psychopharmacol., 30, No. 2, 135–144 (2010).
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 113, No. 11, Iss 2, Depression, pp. 53–58, November, 2013.
About this article
Cite this article
Pribytkov, A.A., Panova, N.B., Popova, Y.V. et al. Efficacy of Agomelatine in Depressive Disorders with Anxiety. Neurosci Behav Physi 45, 393–397 (2015). https://doi.org/10.1007/s11055-015-0087-7
- sleep disorders